Combivir and Hepatitis fulminant - a phase IV clinical study of FDA data

Summary:

Hepatitis fulminant is reported as a side effect among people who take Combivir (lamivudine; zidovudine), especially for people who are female, 30-39 old, have been taking the drug for 1 - 6 months also take Viramune, and have Fever.

The phase IV clinical study analyzes which people have Hepatitis fulminant when taking Combivir. It is created by eHealthMe based on reports of 15,371 people who have side effects when taking Combivir from the FDA, and is updated regularly.

What is Combivir?

Combivir has active ingredients of lamivudine; zidovudine. It is often used in hiv infection. eHealthMe is studying from 15,450 Combivir users. Check the latest studies of Combivir.

What is Hepatitis fulminant?

Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function) is found to be associated with 449 drugs and 677 conditions by eHealthMe. Check the latest studies of Hepatitis fulminant.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

15,371 people reported to have side effects when taking Combivir.
Among them, 44 people (0.29%) have Hepatitis fulminant.

Could Combivir cause Hepatitis fulminant?

Among these 44 people:

How long have people been on Combivir when they have Hepatitis fulminant? *

What is the gender of people who have Hepatitis fulminant when taking Combivir? *

female: 56.1 %
male: 43.9 %

What is the age of people who have Hepatitis fulminant when taking Combivir? *

What are other drugs people take besides Combivir? *

What are other side effects people have besides Hepatitis fulminant? *

Hepatic Encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure): 13 people, 29.55%
Fever: 9 people, 20.45%
Fatty Liver: 8 people, 18.18%
Lactic Acidosis (low ph in body tissues): 7 people, 15.91%
Hepatic Failure (liver failure): 5 people, 11.36%
Hypersensitivity: 5 people, 11.36%
Blood Creatinine Increased: 5 people, 11.36%
Hepatocellular Damage (liver damage): 5 people, 11.36%
Hepatitis B Antibody Positive: 5 people, 11.36%
Cough: 5 people, 11.36%

What are the existing conditions these people have? *

Typhoid Fever: 2 people, 4.55%
Malaria (a parasitic disease due to mosquito bite): 2 people, 4.55%
Fever: 2 people, 4.55%
Stress And Anxiety: 1 person, 2.27%
Premature Labor: 1 person, 2.27%
Major Depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings): 1 person, 2.27%
Birth Control: 1 person, 2.27%
Bipolar Disorder (mood disorder): 1 person, 2.27%
Bacterial Infection: 1 person, 2.27%
Alcoholism (problems with alcohol): 1 person, 2.27%

* Approximation only. Some reports may have incomplete information.

Do you take Combivir and have Hepatitis fulminant?

- Check whether Hepatitis fulminant is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Combivir:

Combivir (15,450 reports)

Browse all side effects of Combivir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis fulminant:

Hepatitis fulminant (449 drugs)

Browse all the conditions that are associated with Hepatitis fulminant:

Hepatitis fulminant (677 conditions)

Related publications that referenced our studies

Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .
Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on lamivudine; zidovudine (the active ingredients of Combivir) and Combivir (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.